目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Biosimilar Contract Manufacturing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Model Analysis
3.4. Product Pipeline Analysis
3.5. Service Pricing Model Analysis
3.6. Technological Advancements
3.7. Supply Chain Analysis
3.8. Biosimilar Contract Manufacturing Market Analysis Tools
3.8.1. Porter’s Five Forces Analysis
3.8.2. PESTEL by SWOT Analysis

Chapter 4. Biosimilar Contract Manufacturing Market: Source Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Biosimilar Contract Manufacturing Market: Source Movement Analysis
4.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
4.4. Mammalian
4.4.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Non-mammalian
4.5.1. Non-mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Biosimilar Contract Manufacturing Market: Service Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Biosimilar Contract Manufacturing Market: Service Movement Analysis
5.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
5.4. Recombinant Non-glycosylated Proteins
5.4.1. Recombinant Non-glycosylated Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Recombinant Glycosylated Proteins
5.5.1. Recombinant Glycosylated Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Biosimilar Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Biosimilar Contract Manufacturing Market: Therapeutic Area Movement Analysis
6.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Blood Disorders
6.5.1. Blood Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Growth Hormonal Deficiency
6.6.1. Growth Hormonal Deficiency Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Chronic & Autoimmune Disorders
6.7.1. Chronic & Autoimmune Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Rheumatoid Arthritis
6.8.1. Rheumatoid Arthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Others
6.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Biosimilar Contract Manufacturing Market: Regional Estimates & Trend Analysis
7.1. Regional Outlook
7.2. Biosimilar Contract Manufacturing Market: Regional Movement Analysis
7.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
7.4. North America
7.4.1. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
7.5.1. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Framework
7.5.5.4. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Framework
7.5.6.4. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Framework
7.5.7.4. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Framework
7.5.8.4. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Framework
7.5.9.4. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Framework
7.6.6.4. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Framework
7.6.7.4. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Framework
7.7.2.4. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Framework
7.7.3.4. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Middle East & Africa
7.8.1. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Framework
7.8.2.4. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Framework
7.8.3.4. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Framework
7.8.4.4. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Framework
7.8.5.4. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.6. Oman
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Framework
7.8.6.4. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.7. Qatar
7.8.7.1. Key Country Dynamics
7.8.7.2. Competitive Scenario
7.8.7.3. Regulatory Framework
7.8.7.4. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape
8.1. Company Categorization
8.1.1. Market Leaders
8.1.2. Emerging Players
8.2. Company Market Assessment Analysis, 2024 (Company Heat Map Analysis)
8.3. Key Company Profiles
8.3.1. Boehringer Ingelheim GmbH
8.3.1.1. Company Overview
8.3.1.2. Financial Performance
8.3.1.3. Product Benchmarking
8.3.1.4. Strategic Initiatives
8.3.2. Lonza
8.3.2.1. Company Overview
8.3.2.2. Financial Performance
8.3.2.3. Product Benchmarking
8.3.2.4. Strategic Initiatives
8.3.3. Rentschler Biopharma SE
8.3.3.1. Company Overview
8.3.3.2. Financial Performance
8.3.3.3. Product Benchmarking
8.3.3.4. Strategic Initiatives
8.3.4. AGC Biologics
8.3.4.1. Company Overview
8.3.4.2. Financial Performance
8.3.4.3. Product Benchmarking
8.3.4.4. Strategic Initiatives
8.3.5. ProBioGen
8.3.5.1. Company Overview
8.3.5.2. Financial Performance
8.3.5.3. Product Benchmarking
8.3.5.4. Strategic Initiatives
8.3.6. FUJIFILM Diosynth Biotechnologies
8.3.6.1. Company Overview
8.3.6.2. Financial Performance
8.3.6.3. Product Benchmarking
8.3.6.4. Strategic Initiatives
8.3.7. Toyobo Co. Ltd.
8.3.7.1. Company Overview
8.3.7.2. Financial Performance
8.3.7.3. Product Benchmarking
8.3.7.4. Strategic Initiatives
8.3.8. Samsung Biologics
8.3.8.1. Company Overview
8.3.8.2. Financial Performance
8.3.8.3. Product Benchmarking
8.3.8.4. Strategic Initiatives
8.3.9. Thermo Fisher Scientific, Inc.
8.3.9.1. Company Overview
8.3.9.2. Financial Performance
8.3.9.3. Product Benchmarking
8.3.9.4. Strategic Initiatives
8.3.10. Binex Co., Ltd.
8.3.10.1. Company Overview
8.3.10.2. Financial Performance
8.3.10.3. Product Benchmarking
8.3.10.4. Strategic Initiatives
8.3.11. WuXi Biologics
8.3.11.1. Company Overview
8.3.11.2. Financial Performance
8.3.11.3. Product Benchmarking
8.3.11.4. Strategic Initiatives
8.3.12. AbbVie, Inc.
8.3.12.1. Company Overview
8.3.12.2. Financial Performance
8.3.12.3. Product Benchmarking
8.3.12.4. Strategic Initiatives
8.3.13. ADMA Biologics, Inc.
8.3.13.1. Company Overview
8.3.13.2. Financial Performance
8.3.13.3. Product Benchmarking
8.3.13.4. Strategic Initiatives
8.3.14. Catalent, Inc
8.3.14.1. Company Overview
8.3.14.2. Financial Performance
8.3.14.3. Product Benchmarking
8.3.14.4. Strategic Initiatives
8.3.15. Cambrex Corporation
8.3.15.1. Company Overview
8.3.15.2. Financial Performance
8.3.15.3. Product Benchmarking
8.3.15.4. Strategic Initiatives
8.3.16. Pfizer Inc.
8.3.16.1. Company Overview
8.3.16.2. Financial Performance
8.3.16.3. Product Benchmarking
8.3.16.4. Strategic Initiatives
8.3.17. Siegfried Holding AG
8.3.17.1. Company Overview
8.3.17.2. Financial Performance
8.3.17.3. Product Benchmarking
8.3.17.4. Strategic Initiatives

List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 4. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, Therapeutic Area, 2021 - 2033 (USD Million)
Table 5. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 6. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
Table 7. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
Table 8. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 9. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 10. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 11. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 12. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 13. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 14. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 15. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 16. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 17. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 18. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 19. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 20. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
Table 21. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 22. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 23. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 24. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 25. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 26. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 27. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 28. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 29. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 30. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 31. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 32. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 33. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 34. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 35. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 36. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 37. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 38. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 39. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 40. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 41. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 42. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 43. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 44. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 45. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 46. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 47. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 48. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
Table 49. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 50. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 51. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 52. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 53. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 54. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 55. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 56. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 57. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 58. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 59. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 60. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 61. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 62. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 63. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 64. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 65. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 66. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 67. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 68. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 69. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 70. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
Table 71. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 72. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 73. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 74. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 75. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 76. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 77. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 78. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 79. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 80. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
Table 81. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 82. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 83. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 84. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 85. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 86. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 87. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 88. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 89. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 90. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 91. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 92. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 93. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 94. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 95. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 96. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 97. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 98. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
Table 99. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
Table 100. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
Table 101. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)

List of Figures
Fig. 1 Biosimilar contract manufacturing market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market dynamics
Fig. 9 Market driver analysis (current & future impact)
Fig. 10 Market restraint analysis (current & future impact)
Fig. 11 Porter’s five forces analysis
Fig. 12 PESTEL by SWOT analysis
Fig. 13 Biosimilar contract manufacturing source key takeaways (USD Million)
Fig. 14 Biosimilar contract manufacturing market: Source, market share 2024 & 2033
Fig. 15 Mammalian biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 16 Non-mammalian biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 17 Biosimilar contract manufacturing therapeutic area key takeaways (USD Million)
Fig. 18 Biosimilar contract manufacturing market: therapeutic area, market share 2024 & 2033
Fig. 19 Oncology biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 20 Blood disorders biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 21 Growth hormonal deficiency biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 22 Chronic & autoimmune disorders biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 23 Rheumatoid arthritis biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 Others biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 Biosimilar contract manufacturing service key takeaways (USD Million)
Fig. 26 Biosimilar contract manufacturing market: service, market share 2024 & 2033
Fig. 27 Recombinant non-glycosylated proteins biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 28 Recombinant glycosylated proteins biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 Regional outlook, 2024 & 2033
Fig. 30 North America biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 U.S. biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 Canada biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 33 Mexico biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 34 Europe biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 UK biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Germany biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 France biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 38 Italy biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 39 Spain biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 40 Denmark biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Sweden biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Norway biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 43 Asia Pacific biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Japan biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 45 China biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 46 India biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 47 Australia biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 South Korea biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 49 Thailand biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 50 Latin America biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 51 Brazil biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 52 Argentina biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 53 MEA biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 54 South Africa biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 55 Saudi Arabia biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 56 UAE biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 57 Kuwait biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 58 Qatar biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 59 Oman biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)